The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
An assessment by the Statin Liver Safety Task Force: 2014 update
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although statins are generally well tolerated, adverse events, such as rhabdomyolysis, and idiosyncratic drug-induced liver injury (DILI) have been well described.2”
From Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge (2025) · cites this paper as [2]
In the citing paper
“The overall incidence rate for statin-induced acute liver failure (ALF) has been reported to be between 1 and 2 per 100,000 person-years.2,5”
From Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge (2025) · cites this paper as [2]
In the citing paper
“Several randomized controlled trials have demonstrated no significant increase in the incidence of persistently elevated serum aminotransferase levels between statin and placebo therapy, including in patients with known chronic liver disease.198–200”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
Self-citationVanWagner, L. B., Bhave, M., Te, H. S., Feinglass, J., Alvarez, L., & Rinella, M. E. (2012) · Hepatology · doi:10.1002/hep.25855 · Cited by 220
Research works printed but not linked: 14
- James, 2014, 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members Appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, 507, 10.1001/jama.2013.284427 · DOI · Paper page
- Stein, 2011, Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia, Circulation, 123, 1974, 10.1161/CIRCULATIONAHA.110.975284 · DOI
- Cohen, 2006, An assessment of statin safety by hepatologists, Am J Cardiol, 97, 77C, 10.1016/j.amjcard.2005.12.014 · DOI · Paper page
- Torres, 2012, Features, diagnosis, and treatment of nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 10, 837, 10.1016/j.cgh.2012.03.011 · DOI · Paper page
- Chatrath, 2012, Dyslipidemia in patients with nonalcoholic fatty liver disease, Semin Liver Dis, 32, 22, 10.1055/s-0032-1306423 · DOI · Paper page
- Athyros, 2010, Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis, Lancet, 376, 1916, 10.1016/S0140-6736(10)61272-X · DOI · Paper page
- Ekstedt, 2007, Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study, J Hepatol, 47, 135, 10.1016/j.jhep.2007.02.013 · DOI · Paper page
- Nelson, 2009, A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial, J Clin Gastroenterol, 43, 990, 10.1097/MCG.0b013e31819c392e · DOI · Paper page
- Alla, 2006, Autoimmune hepatitis triggered by statins, J Clin Gastroenterol, 40, 757, 10.1097/00004836-200609000-00018 · DOI
- Russo, 2009, Drug-induced liver injury associated with statins, Semin Liver Dis, 29, 412, 10.1055/s-0029-1240010 · DOI · Paper page
- John, 2013, Statins as a Potential risk factor for autoimmune diseases: a case report and review [e-pub ahead of print], Am J Ther, 10.1097/MJT.0b013e31828e5bfb · doi:10.1097/mjt.0b013e31828e5bfb
- Lardizabal, 2010, Benefits of statin therapy and compliance in high risk cardiovascular patients, Vasc Health Risk Manag, 6, 843
- Davern, 2011, Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury, Gastroenterology, 141, 1665, 10.1053/j.gastro.2011.07.051 · DOI · Paper page
- D'Agata, 1999, Evaluation of liver disease in the pediatric patient, Pediatr Rev, 20, 376, 10.1542/pir.20-11-376 · doi:10.1542/pir.20-11-376
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Melatonin as an antioxidant: under promises but over delivers
Reiter, R. J., Mayo, J. C., Tan, D., Sainz, R. M., Alatorre‐Jimenez, M., & Qin, L. (2016) · Journal of Pineal Research · doi:10.1111/jpi.12360 · Cited by 1,703
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Metadata
- Authors
- Bays, H., Cohen, D. E., Chalasani, N., & Harrison, S. A.
- Venue
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 8
- Issue
- 3
- Pages
- S47-S57
- ISSN
- 1933-2874
- Cited by
- 187
- References
- 7
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An assessment by the Statin Liver Safety Task Force: 2014 update. https://app.cochat.ai/papers/10.1016/j.jacl.2014.02.011
- The paper
- Bays, H., Cohen, D. E., Chalasani, N., & Harrison, S. A. (2014). An assessment by the Statin Liver Safety Task Force: 2014 update. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2014.02.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.